CANCER:

Prostate Cancer

News alerts, weekly reports and conference planners

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	enzalutamide capsule Sensitive: A1 - Approval FDA - 2 weeks (New A1) enzalutamide capsule Sensitive : A1 FDA - 2wk	enzalutamide capsule Sensitive: A1 - Approval FDA - 2 weeks enzalutamide capsule Sensitive : A1 FDA - 2 weeks - (New A1)
FOLH1 positive	Prostate Cancer	FOLH1 positive	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval Canada Newswire - 2 weeks (New A1) lutetium Lu 177 vipivotide tetraxetan Sensitive : A1 Canada Newswire - 2wk	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval Canada Newswire - 2 weeks lutetium Lu 177 vipivotide tetraxetan Sensitive : A1 Canada Newswire - 2 weeks - (New A1)
SPOP mutation	Prostate Cancer	SPOP mutation	Prostate Cancer	Androgen receptor inhibitor Sensitive: C3 – Early Trials Clin Cancer Res - 2 weeks (New C3) Androgen receptor inhibitor Sensitive : C3 Clin Cancer Res - 2wk	Androgen receptor inhibitor Sensitive: C3 – Early Trials Clin Cancer Res - 2 weeks Androgen receptor inhibitor Sensitive : C3 Clin Cancer Res - 2 weeks - (New C3)
SPOP mutation	Prostate Cancer	SPOP mutation	Prostate Cancer	enzalutamide capsule + abiraterone acetate + apalutamide Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) enzalutamide capsule + abiraterone acetate + apalutamide Sensitive : C3 ESMO 2022 - 3wk	enzalutamide capsule + abiraterone acetate + apalutamide Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks enzalutamide capsule + abiraterone acetate + apalutamide Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
AR wild-type	Prostate Cancer	AR wild-type	Prostate Cancer	abiraterone acetate Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) abiraterone acetate Sensitive : C3 ESMO 2022 - 3wk	abiraterone acetate Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks abiraterone acetate Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
AR wild-type	Prostate Cancer	AR wild-type	Prostate Cancer	enzalutamide capsule Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) enzalutamide capsule Sensitive : C3 ESMO 2022 - 3wk	enzalutamide capsule Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks enzalutamide capsule Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
HRD	Prostate Cancer	HRD	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	leuprolide mesylate injectable suspension Sensitive: A1 - Approval leuprolide mesylate injectable suspension Sensitive : A1	leuprolide mesylate injectable suspension Sensitive: A1 - Approval leuprolide mesylate injectable suspension Sensitive : A1
MSI-H/dMMR	Prostate Cancer	MSI-H/dMMR	Prostate Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	mitoxantrone Sensitive: A2 - Guideline mitoxantrone Sensitive : A2	mitoxantrone Sensitive: A2 - Guideline mitoxantrone Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
PALB2 mutation	Prostate Cancer	PALB2 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
CHEK2 mutation	Prostate Cancer	CHEK2 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
CHEK1 mutation	Prostate Cancer	CHEK1 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	abiraterone acetate Resistant: A2 - Guideline abiraterone acetate Resistant : A2	abiraterone acetate Resistant: A2 - Guideline abiraterone acetate Resistant : A2
AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	enzalutamide capsule Resistant: A2 - Guideline enzalutamide capsule Resistant : A2	enzalutamide capsule Resistant: A2 - Guideline enzalutamide capsule Resistant : A2
RAD51B mutation	Prostate Cancer	RAD51B mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
RAD51C mutation	Prostate Cancer	RAD51C mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
RAD51D mutation	Prostate Cancer	RAD51D mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
RAD54L mutation	Prostate Cancer	RAD54L mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
FANCL mutation	Prostate Cancer	FANCL mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2

Prostate Cancer

Associations(401)

Associations
(401)